{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:19:13Z","timestamp":1788250753042,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Acute coronary syndrome (ACS) is a critical clinical emergency resulting from the rupture or erosion of coronary atherosclerotic plaques and subsequent thrombosis. Its pathogenesis is driven by a complex interplay of dysregulated lipid metabolism, inflammatory responses, thrombotic processes, and genetic susceptibility. Although traditional lipid parameters are widely utilized in ACS risk assessment, they remain limited in their ability to account for residual cardiovascular risk, inherited lipid abnormalities, and the overall atherosclerotic burden. Lipoprotein(a) [Lp(a)], an independent, genetically determined cardiovascular risk factor, exhibits distinctive pro-atherogenic, pro-inflammatory, and pro-thrombotic properties. In parallel, the apolipoprotein B\/apolipoprotein A-I (ApoB\/ApoA-I) ratio reflects the equilibrium between atherogenic lipoprotein particles and anti-atherogenic lipoprotein functions, providing a more comprehensive measure of lipid-related metabolic risk. Recent evidence has highlighted the value of both biomarkers in assessing coronary lesion severity, plaque instability, and prognosis in ACS. This review synthesizes current findings regarding the pathophysiological basis, clinical utility, and potential for combined assessment of Lp(a) and the ApoB\/ApoA-I ratio, while critically discussing the limitations of existing research. Future investigations should shift from univariate biomarker analysis toward multi-marker integration, risk reclassification, genetic stratification, and validation of targeted interventions to advance precision risk assessment and individualized management of ACS.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1937328","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:08:15Z","timestamp":1788250095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical utility of lipoprotein(a) and the ApoB\/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification"],"prefix":"10.3389","volume":"13","author":[{"given":"Zuqiang","family":"Lu","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankui","family":"Li","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Li","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xi'an Ninth Hospital","place":["Xi'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Li","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Third Clinical Medical College of Ningxia Medical University, People's Hospital of Ningxia Hui Autonomous Region","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4140810","DOI":"10.1161\/circ.150.suppl_1.4140810","article-title":"Abstract 4140810: impact of neutrophil on ischemic risk in acute coronary syndrome patients across different low density lipoprotein cholesterol levels","volume":"150","author":"Yan","year":"2024","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/biom12010026","article-title":"Lipoprotein(a)\u2014the crossroads of atherosclerosis, atherothrombosis and inflammation","volume":"12","author":"Ugov\u0161ek","year":"2021","journal-title":"Biomolecules"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1161\/01.ATV.0000035521.22199.C7","article-title":"Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men","volume":"22","author":"Talmud","year":"2002","journal-title":"ATVB"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new Serum type system in man\u2014the lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"B8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e003737","DOI":"10.1161\/CIRCGEN.122.003737","article-title":"Value of genetic testing for lipoprotein(a) variants","volume":"15","author":"Langsted","year":"2022","journal-title":"Circ Genom Precis Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/00365513.2010.550311","article-title":"Lipoprotein(a) and risk of myocardial infarction \u2013 genetic epidemiologic evidence of causality","volume":"71","author":"Kamstrup","year":"2011","journal-title":"Scand J Clin Lab Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.amjcard.2013.05.009","article-title":"Validation and quantification of genetic determinants of lipoprotein-a levels and predictive value for angiographic coronary artery disease","volume":"112","author":"Anderson","year":"2013","journal-title":"Am J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2174\/0929867324666170120155412","article-title":"Lipoprotein (a) evolution: possible benefits and harm. Genetic and non-genetic factors influencing its plasma levels","volume":"24","author":"Kostakou","year":"2017","journal-title":"CMC"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2018.07.002","article-title":"Apolipoprotein(a) inhibits the conversion of glu-plasminogen to lys-plasminogen on the surface of vascular endothelial and smooth muscle cells","volume":"169","author":"Romagnuolo","year":"2018","journal-title":"Thromb Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2174\/157016111797484071","article-title":"Lipoprotein(a): current perspectives","volume":"9","author":"Gouni-Berthold","year":"2011","journal-title":"CVP"},{"key":"B17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van Der Valk","year":"2016","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e002382","DOI":"10.1136\/openhrt-2023-002382","article-title":"Ancestral diversity in lipoprotein(a) studies helps address evidence gaps","volume":"10","author":"Lee","year":"2023","journal-title":"Open Heart"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"ATVB"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ehad655.1437","DOI":"10.1093\/eurheartj\/ehad655.1437","article-title":"Association of lipoprotein(a) with severity of coronary artery atherosclerosis in patients with acute coronary syndromes","volume":"44","author":"Koziel-Siolkowska","year":"2023","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.17116\/Cardiobulletin20252002137","article-title":"Hyperlipoproteinemia(a) and its impact on prognosis in patients with acute coronary syndrome","volume":"20","author":"Bliznyuk","year":"2025","journal-title":"Rus Cardio Bull"},{"key":"B22","doi-asserted-by":"publisher","first-page":"ehz745.0962","DOI":"10.1093\/eurheartj\/ehz745.0962","article-title":"P4572Lipoprotein(a) is not associated with survival after acute coronary syndromes","volume":"40","author":"Roth","year":"2019","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"117437","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and Major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"v181","DOI":"10.1093\/eurheartjsupp\/suag048","article-title":"Focus on lipoprotein(a)","volume":"28","author":"Biolo","year":"2026","journal-title":"Eur. Heart J. Suppl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40256-021-00499-1","article-title":"A review of the clinical pharmacology of pelacarsen: a lipoprotein(a)-lowering agent","volume":"22","author":"Hardy","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13499","DOI":"10.3390\/ijms232113499","article-title":"Atherogenic lipoproteins for the statin residual cardiovascular disease risk","volume":"23","author":"Yanai","year":"2022","journal-title":"IJMS"},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0079-6107(03)00028-2","article-title":"On the structure and function of apolipoproteins: more than a family of lipid-binding proteins","volume":"83","author":"Bolanos-Garcia","year":"2003","journal-title":"Prog Biophys Mol Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCRESAHA.119.315019","article-title":"Apob: the power of physiology to transform the prevention of cardiovascular disease","volume":"124","author":"Sniderman","year":"2019","journal-title":"Circ Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1515\/cclm-2013-0358","article-title":"Recent advances in physiological lipoprotein metabolism","volume":"52","author":"Ramasamy","year":"2014","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jprot.2014.04.030","article-title":"Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins","volume":"106","author":"Von Zychlinski","year":"2014","journal-title":"J Proteomics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1016\/S0021-9258(19)39010-6","article-title":"Human apolipoprotein A-IV binds to apolipoprotein A-I\/A-II receptor sites and promotes cholesterol efflux from adipose cells","volume":"265","author":"Steinmetz","year":"1990","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","article-title":"The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy \u2013 a review of the evidence","volume":"259","author":"Walldius","year":"2006","journal-title":"J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.2337\/dc12-2388","article-title":"Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12933-024-02140-2","article-title":"Revisiting an old relationship: the causal associations of the ApoB\/ApoA1 ratio with cardiometabolic diseases and relative risk factors\u2014a Mendelian randomization analysis","volume":"23","author":"Fu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e32084","DOI":"10.1016\/j.heliyon.2024.e32084","article-title":"A potentially underestimated predictor of coronary artery disease risk: the ApoB\/ApoA1 ratio","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e014038","DOI":"10.1136\/bmjopen-2016-014038","article-title":"Associations of apolipoprotein B\/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults","volume":"7","author":"Zheng","year":"2017","journal-title":"BMJ Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1161\/ATVBAHA.125.323157","article-title":"Estimated small, dense LDL cholesterol and atherosclerotic cardiovascular risk in the UK biobank","volume":"45","author":"Zubiran","year":"2025","journal-title":"ATVB"},{"key":"B39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12872-020-01562-6","article-title":"Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB\/ApoA1","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2603463","DOI":"10.1080\/10641963.2025.2603463","article-title":"The ApoB\/ApoA-I ratio supersedes conventional lipids in predicting coronary artery disease and clinical phenotypes requiring revascularization","volume":"48","author":"Jiang","year":"2026","journal-title":"Clin Exp Hypertens"},{"key":"B41","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population","volume":"30","author":"Sierra-Johnson","year":"2008","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)12663-3","article-title":"Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment","volume":"361","author":"Sniderman","year":"2003","journal-title":"The Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"A18449","DOI":"10.1161\/circ.132.suppl_3.18449","article-title":"Abstract 18449: apolipoprotein B\/apolipoprotein A-I ratio and progression of aortic valve stenosis - results from the PROGRESSA study","volume":"132","author":"Tastet","year":"2015","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/591454","article-title":"The apolipoprotein B\/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity","volume":"2015","author":"Kaneva","year":"2015","journal-title":"Dis Markers"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1253\/circj.CJ-19-1097","article-title":"Apolipoprotein B\/A-I ratio predicts lesion severity and clinical outcomes in diabetic patients with acute coronary syndrome","volume":"84","author":"Liu","year":"2020","journal-title":"Circ J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.atherosclerosis.2023.06.213","article-title":"Genetic testing on LPA gene variants in the prevention of cardiovascular events","volume":"379","author":"Knack","year":"2023","journal-title":"Atherosclerosis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"44003","DOI":"10.31083\/RCM44003","article-title":"Lipoprotein(a) and high-risk coronary plaques: mechanisms, characteristics, and emerging therapeutic strategies","volume":"26","author":"Fang","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ehf2.14547","article-title":"Serum apolipoprotein B to apolipoprotein A-I ratio predicts mortality in patients with heart failure","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Failure"},{"key":"B49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e013020","DOI":"10.1161\/JAHA.119.013020","article-title":"Apob\/apoA-I ratio and lp(a) associations with aortic valve stenosis incidence: insights from the EPIC-norfolk prospective population study","volume":"8","author":"Zheng","year":"2019","journal-title":"JAHA"},{"key":"B52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/clinchem\/hvaa054","article-title":"Analytical performance specifications for lipoprotein(a), apolipoprotein B-100, and apolipoprotein A-I using the biological variation model in the EuBIVAS population","volume":"66","author":"Clouet-Foraison","year":"2020","journal-title":"Clin Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1080\/14656566.2025.2601062","article-title":"Lipoprotein(a) \u2013 treatments in development.","volume":"26","author":"Tomlinson","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e14254","DOI":"10.1111\/eci.14254","article-title":"New insights into the therapeutic options to lower lipoprotein(a)","volume":"54","author":"Baragetti","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2796.2006.01648.x","article-title":"Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels","volume":"259","author":"Marcovina","year":"2006","journal-title":"J Intern Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12944-022-01733-8","article-title":"Associations of lipid measures with total occlusion in patients with established coronary artery disease: a cross-sectional study","volume":"21","author":"Li","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1003853","DOI":"10.1371\/journal.pmed.1003853","article-title":"Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB\/apoA-1 ratio\u2014experience from the Swedish AMORIS cohort: a cohort study","volume":"18","author":"Walldius","year":"2021","journal-title":"PLoS Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.ajpc.2025.100945","article-title":"Rethinking cardiovascular risk: the emerging role of lipoprotein(a) screening","volume":"21","author":"Clair","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e029223","DOI":"10.1161\/JAHA.122.029223","article-title":"Lipoprotein(a) genotype influences the clinical diagnosis of familial hypercholesterolemia","volume":"12","author":"Olmastroni","year":"2023","journal-title":"JAHA"},{"key":"B62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"13622","DOI":"10.3390\/ijms241713622","article-title":"Novel pharmacological therapies for the management of hyperlipoproteinemia(a)","volume":"24","author":"Kosmas","year":"2023","journal-title":"IJMS"},{"key":"B64","doi-asserted-by":"publisher","first-page":"103695","DOI":"10.1016\/j.jpet.2025.103695","article-title":"Emerging therapies targeting lipoprotein(a): pharmacologic advances and future directions","volume":"392","author":"Perez","year":"2025","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1937328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:08:16Z","timestamp":1788250096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1937328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":64,"alternative-id":["10.3389\/fcvm.2026.1937328"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1937328","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1937328"}}